Search Results - "Neidhart, Jeffrey D"

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia by Salama, Carlos, Han, Jian, Yau, Linda, Reiss, William G, Kramer, Benjamin, Neidhart, Jeffrey D, Criner, Gerard J, Kaplan-Lewis, Emma, Baden, Rachel, Pandit, Lavannya, Cameron, Miriam L, Garcia-Diaz, Julia, Chávez, Victoria, Mekebeb-Reuter, Martha, Lima de Menezes, Ferdinando, Shah, Reena, González-Lara, Maria F, Assman, Beverly, Freedman, Jamie, Mohan, Shalini V

“…In a randomized trial, the risk of mechanical ventilation or death among patients hospitalized with Covid-19 pneumonia (56.0% Hispanic or Latino, 14.9% Black,…”
Get full text

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies by Weiss, Glen J., Chao, Joseph, Neidhart, Jeffrey D., Ramanathan, Ramesh K., Bassett, Dawn, Neidhart, James A., Choi, Chung Hang J., Chow, Warren, Chung, Vincent, Forman, Stephen J., Garmey, Edward, Hwang, Jungyeon, Kalinoski, D. Lynn, Koczywas, Marianna, Longmate, Jeffrey, Melton, Roger J., Morgan, Robert, Oliver, Jamie, Peterkin, Joanna J., Ryan, John L., Schluep, Thomas, Synold, Timothy W., Twardowski, Przemyslaw, Davis, Mark E., Yen, Yun

“…Summary Patients with advanced solid malignancies were enrolled to an open-label, single-arm, dose-escalation study, in which CRLX101 was administered…”
Get full text

Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen by Afari, Jonathan, Spektor, Tanya M., Turner, Carley, Cohen, Alexa, Bessudo, Alberto, Jhangiani, Haresh, Gabrail, Nashat, Kubba, Samir, Neidhart, Jeffrey D., Eshaghian, Shahrooz, Swift, Regina A., Eades, Benjamin M., Kim, Clara, Kim, Susanna, Vescio, Robert, Berenson, James R.

“…•Pomalidomide is possibly a replacement drug for myeloma patients refractory to lenalidomide.•Pomalidomide achieves responses among myeloma patients refractory…”
Get full text

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer by Garon, Edward B, Neidhart, Jeffrey D, Gabrail, Nashat Y, de Oliveira, Moacyr R, Balkissoon, Jai, Kabbinavar, Fairooz

“…Combretastatin A4-phosphate, fosbretabulin tromethamine (CA4P) is a vascular disrupting agent that targets tumor vasculature. This study evaluated the safety…”
Get full text

Efficacy and safety of pomalidomide as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma patients refractory to a lenalidomide-containing combination regimen by Berenson, James R., Cohen, Alexa, Spektor, Tanya M., Lashkari, Ashkan, Mackintosh, Roy, Bessudo, Alberto, Robinson, Michael Oren, Jhangiani, Haresh S., Gabrail, Nashat Y., Nakhoul, Ibrahim, Kubba, Samir V., Neidhart, Jeffrey D., Maluso, Tina, Swift, Regina A., Vescio, Robert A.

“…Abstract only…”
Get full text

Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen by Berenson, James R, Cohen, Alexa, Spektor, Tanya M., Lashkari, Ashkan, Mackintosh, Roy, Bessudo, Alberto, Jhangiani, Haresh, Gabrail, Nashat, Nakhoul, Ibrahim, Kubba, Samir, Neidhart, Jeffrey D., Tina, Maluso, Swift, Regina, Vescio, Robert

“…Introduction Pomalidomide (POM) is an immunomodulatory drug shown to be safe and effective for the treatment of relapsed/refractory multiple myeloma (RRMM)…”
Get full text

Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study by Townsend, William, Buske, Christian, Cartron, Guillaume, Cunningham, David, Dyer, Martin JS, Gribben, John G., Hess, Georg, Ishikawa, Takayuki, Keller, Ulrich, Kneba, Michael, Malladi, Ram, Neidhart, Jeffrey D, Rusconi, Chiara, Zhu, Jun, Catalani, Olivier, Knapp, Andrea, Zeuner, Harald, Herold, Michael, Hiddemann, Wolfgang, Marcus, Robert

“…Introduction: Immunochemotherapy is standard of care treatment for previously untreated patients (pts) with advanced stage follicular lymphoma (FL). However,…”
Get full text

Analysis of efficacy and safety of POM as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma pts refractory to a lenalidomide-containing combination regimen by Berenson, James R., Cohen, Alexa, Spektor, Tanya M., Lashkari, Ashkan, Mackintosh, Roy, Bessudo, Alberto, Robinson, Michael Oren, Jhangiani, Haresh S., Gabrail, Nashat Y., Nakhoul, Ibrahim, Kubba, Samir V., Neidhart, Jeffrey D., Maluso, Tina, Swift, Regina A., Vescio, Robert A., Eshaghian, Shahrooz

“…Abstract only e19528 Background: Pomalidomide (POM) is a third –generation immunomodulatory drug shown to be safe and effective for the treatment of…”
Get full text

B-F1RST: Assessment of novel blood-based biomarkers in patients with first-line advanced or metastatic NSCLC receiving atezolizumab monotherapy by Kim, Edward S., Socinski, Mark A., Dakhil, Shaker R., Mackler, Niklas J., Ikhlaque, Nadeem, Mekhail, Tarek, Volterra, Fabio, El Khoury, Christian Antoine, Schiller, Joan H., Tsai, Michaela L., Hayek, Fadi, Neidhart, Jeffrey D., Hunis, Brian, Hu, Sylvia, Paul, Sarah M., Shames, David S., Phan, See-Chun, Yun, Cindy, Velcheti, Vamsidhar

“…Abstract only TPS9103 Background: The anti–PD-L1 monoclonal antibody atezolizumab inhibits the interaction of PD-L1 with its receptors PD-1 and B7.1, thereby…”
Get full text

A randomized Phase II trial of the tumor vascular disrupting agent CA4P by Garon, Edward B, Neidhart, Jeffrey D, Kabbinavar, Fairooz, Gabrail, Nashat Y, Balkissoon, Jai, de Oliveira, Moacyr R

Get full text

Abstract A97: Final phase 1/2a results evaluating the cyclodextrin-containing nanoparticle CRLX101 in patients with advanced solid tumor malignancies by Yen, Yun, Coerver, Lori A., Garmey, Edward G., Kalinoski, D. Lynn, Koczywas, Marianna, Neidhart, James A., Neidhart, Jeffrey D., Peterkin, Joanna J., Ramanathan, Ramesh K., Ryan, John, Weiss, Glen J.

“…Introduction: Topoisomerase-1-inhibiting camptothecin (CPT) and derivatives such as irinotecan (CPT-11) and topotecan demonstrate clinical utility across…”
Get full text